Silexion Therapeutics Corp Amends Charter to Increase Authorized Shares

What Happened
Silexion Therapeutics Corp filed an 8-K reporting that shareholders approved an amendment to paragraph 5 of the company’s amended and restated memorandum of association to increase the company’s authorized share capital. The amendment was approved at an extraordinary general meeting originally held July 13, 2026 and reconvened July 20, 2026, and was filed with the Registrar of Companies of the Cayman Islands on July 21, 2026, at which time it became effective. The Memorandum Amendment is attached as Exhibit 3.1 to the filing.

Key Details

• Shareholder vote: Extraordinary general meeting held July 13, 2026 and reconvened July 20, 2026; resolution approving the amendment was duly approved.
• Amendment: Changes paragraph 5 of the company’s amended and restated memorandum of association to increase authorized share capital.
• Effective date: Memorandum Amendment filed with the Cayman Islands Registrar on July 21, 2026 and became effective that day.
• Filing reference: Memorandum Amendment included as Exhibit 3.1 to the 8-K (Items 5.03/5.07 reported).

Why It Matters
An increase in authorized share capital does not itself issue new shares but gives the company the legal ability to issue additional shares in the future. That flexibility can be used for financing, acquisitions, or equity compensation and may lead to dilution if new shares are issued. Investors who want the exact new authorized share amount and the specific terms should review the Memorandum Amendment (Exhibit 3.1) filed with the 8-K. No immediate share issuance was reported in this filing.